Annual report pursuant to Section 13 and 15(d)

Accrued Expenses and Other Current Liabilities

v3.20.1
Accrued Expenses and Other Current Liabilities
12 Months Ended
Dec. 31, 2019
Accrued Expenses and Other Current Liabilities  
Accrued Expenses and Other Current Liabilities

5. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

December 31, 

 

    

2019

    

2018

Compensation and benefits

 

$

1,786

 

$

1,524

Restructuring (severance)

 

 

 —

 

 

1,419

Pharmaceutical development expenses

 

 

445

 

 

231

Accrued interest

 

 

18

 

 

88

Other accrued expenses and other current liabilities

 

 

154

 

 

33

Total accrued expenses and other current liabilities

 

$

2,403

 

$

3,295